Insight

Jun 8, 2024, 09:58

Angelo Pirozzi: Circulating immune-related proteins might predict the efficacy of Immune Checkpoint Inhibitors

Angelo Pirozzi, Research Fellow at Mayo Clinic, shared on X: .

“92 Circulating-immuno-oncology-related proteins in patients with metastatic PDAC (Pancreatic Ductal Adenocarcinoma) from the CheckPAC trial who responded to radiotherapy +nivolumab ± ipilimumab.

High FASLG (FAS ligand) and Gal-1 lead to higher PFS (progression-free survival)

Circulating immune-related proteins might predict the efficacy of ICIs (Immune Checkpoint Inhibitors).”

Proceed to the article.
Source: Angelo Pirozzi/X

Angelo Pirozzi cancer CheckPAC FASLG Immune checkpoint inhibitors (ICIs) immune-related proteins ipilimumab Mayo Clinic metastatic PDAC nivolumab OncoDaily Oncology pancreatic ductal adenocarcinoma PDAC PFS

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage